News - Tecfidera, Eloctate

Filter

Current filters:

TecfideraEloctate

Popular Filters

Positive Ph III pediatric data for investigational hemophilia A drug Eloctate

Positive Ph III pediatric data for investigational hemophilia A drug Eloctate

10-04-2014

US biotech firm Biogen Idec and Swedish Orphan Biovitrum today released positive top-line results of…

Biogen IdecEloctateHematologyResearchSwedish Orphan Biovitrum

NICE asks Biogen Idec for more information on Tecfidera

NICE asks Biogen Idec for more information on Tecfidera

21-02-2014

The UK’s National Institute for Health and Care Excellence (NICE) is calling on US biotech firm Biogen…

Biogen IdecBiotechnologyCNS DiseasesRegulationTecfideraUK

Biogen’s MS drug Tecfidera approved in EU

Biogen’s MS drug Tecfidera approved in EU

03-02-2014

US biotech firm Biogen Idec’s Tecfidera (dimethyl fumarate) has been approved by the European Commission…

Biogen IdecBiotechnologyEuropeNeurologicalRegulationTecfidera

UCB and Biogen sign Asian license agreement for MS drugs

UCB and Biogen sign Asian license agreement for MS drugs

30-01-2014

Belgian drugmaker UCB and US biotech firm Biogen Idec have signed exclusive agreements granting UCB the…

AlprolixAsia-PacificBiogen IdecBiotechnologyEloctateLicensingNeurologicalPharmaceuticalTecfideraUCB

Biogen Idec beats on sales and earnings, with shinning performance from Tecfidera

Biogen Idec beats on sales and earnings, with shinning performance from Tecfidera

29-01-2014

US biotech firm Biogen Idec reported full year and fourth quarter 2013 results that beat consensus Wall…

Biogen IdecBiotechnologyFinancialTecfidera

Royalty Pharma acquires additional interest in Tecfidera for $510 million

Royalty Pharma acquires additional interest in Tecfidera for $510 million

06-01-2014

US private equity firm Royalty Pharma says that it has acquired an additional interest in the earn-out…

Biogen IdecDermatologicalsFumadermFumapharmLicensingNeurologicalPharmaceuticalRoyalty PharmaTecfidera

ASH 2013: Meeting highlights from Novartis, Takeda, Biogen Idec and SOBI

ASH 2013: Meeting highlights from Novartis, Takeda, Biogen Idec and SOBI

10-12-2013

This year’s American Society of Hematology (ASH) meeting continued yesterday with more clinical trial…

Biogen IdecEloctateHematologyJakaviNovartisPharmaceuticalResearchSobiTakeda PharmaceuticalsUSA

Biogen prevails in EU exclusivity battle for MS drug Tecfidera

Biogen prevails in EU exclusivity battle for MS drug Tecfidera

25-11-2013

US biotech company Biogen Idec saw its shares leap 10% to an all-time high of nearly $278 on Friday,…

Biogen IdecBiotechnologyEuropeNeurologicalPatentsRegulationTecfidera

2013 FDA approval rates suggest record year for post-launch success

14-11-2013

A focus on hard to treat or specialist diseases is set to result in record post-launch sales for new…

Biogen IdecFinancialGilead SciencesNorth AmericaPharmaceuticalRegulationsofosbuvirTecfidera

Biogen and SOBI announce top line results for hemophilia A treatment Eloctate

Biogen and SOBI announce top line results for hemophilia A treatment Eloctate

14-11-2013

US biotech major Biogen Idec (Nasdaq: BIIB) and Swedish Orphan Biovitrum (STO: SOBI) have announced detailed…

Biogen IdecBiotechnologyEloctateHematologyNorth AmericaResearchSobiUSA

US FDA calls for further data on Biogen Idec’s Eloctate

US FDA calls for further data on Biogen Idec’s Eloctate

13-11-2013

Swedish Orphan Biovitrum has announced that its partner, US biotech major Biogen Idec, has received a…

Biogen IdecBiotechnologyEloctateHematologyNorth AmericaRegulationSwedish Orphan Biovitrum

Biogen Idec 3rd-qtr beats on revenues and earnings

Biogen Idec 3rd-qtr beats on revenues and earnings

28-10-2013

US biotech firm Biogen Idec says its net income for the third-quarter of 2013 rose to $487.6 million,…

Biogen IdecBiotechnologyFinancialTecfidera

Biogen Idec presents new Tecfidera data in MS at ECTRIMS

04-10-2013

Biogen Idec presented data showing that Tecfidera continues to offer consistent and strong efficacy combined…

Biogen IdecBiotechnologyNeurologicalResearchTecfidera

Mixed US views on Gilenya, Aubagio and Tecfidera as breakthrough MS drugs

03-09-2013

More than half of surveyed neurologists consider US biotech firm Biogen Idec's (Nasdaq: BIIB) Tecfidera…

AubagioBiogen IdecGilenyaMarkets & MarketingNeurologicalNorth AmericaNovartisPharmaceuticalPricingSanofiTecfidera

Multiple sclerosis market could reach $18.3 billion in 2018

19-08-2013

The multiple sclerosis (MS) market is expected to peak at $18.3 billion in 2018, according to healthcare…

AubagioBiogen IdecFinancialGilenyaGlobalNovartisPharmaceuticalSanofiTecfidera

Biogen Idec beats expectations in 2nd-qtr, helped by Tecfidera launch

25-07-2013

US biotech firm Biogen Idec (Nasdaq: BIIB) has reported second quarter 2013 total revenues of $1.7 billion,…

AvonexBiogen IdecBiotechnologyFinancialNorth AmericaRituxanTecfideraTysabri

Alkermes reveals candidates for MS, cancer and pain

18-07-2013

US drugmaker Alkermes (Nasdaq: ALKS) has unveiled three new drug candidates for the treatment of multiple…

AlkermesBiogen IdecNeurologicalNorth AmericaOncologyPharmaceuticalResearchTecfidera

New data supports safety of Biogen and SOBI's Eloctate for hemophilia A

05-07-2013

US biotech firm Biogen Idec (Nasdaq: BIIB) and Stockholm-based Swedish Orphan Biovitrum (STO: SOBI) have…

AlprolixBiogen IdecEloctatePharmaceuticalResearchSobi

Biogen Idec sees EU launch delay for Tecfidera on patent issues

31-05-2013

In a filing with the Securities and Exchange Commission, US biotech firm Biogen Idec (Nasdaq: BIIB) said…

Biogen IdecBiotechnologyEuropeMarkets & MarketingNeurologicalPatentsRegulationTecfidera

FDA approves Biogen Idec's new multiple sclerosis treatment Tecfidera

28-03-2013

The US Food and Drug Administration yesterday (March 27) approved biotech firm Biogen Idec's (Nasdaq:…

BG-12Biogen IdecBiotechnologyNeurologicalNorth AmericaRegulationTecfidera

Back to top